Diagnostic performance of the T-MACS model as a ‘rule out’ test (ie, ‘very low risk’ vs all other groups) in the derivation and validation cohorts
| Derivation set (n=703) | Validation study (n=1459) | |||
|---|---|---|---|---|
| For AMI | For ACS | For AMI | For ACS | |
| Sensitivity | 99.2 (95.8–100.0) | 98.7 (95.3–99.8) | 98.8 (95.9–99.9) | 98.1 (95.2–99.5) |
| Specificity | 46.1 (41.9–50.3) | 47.6 (43.4–51.9) | 45.7 (42.9–48.5) | 47.0 (44.2–49.8) |
| Positive predictive value | 29.5 (25.2–34.0) | 34.0 (29.6–38.7) | 19.6 (17.0–22.4) | 23.9 (21.1–26.9) |
| Negative predictive value | 99.6 (97.9–100.0) | 99.3 (97.3–99.9) | 99.7 (98.8–100.0) | 99.3 (98.3–99.8) |
| Positive likelihood ratio | 1.84 (1.70–1.99) | 1.88 (1.74–2.05) | 1.82 (1.73–1.92) | 1.85 (1.75–1.96) |
| Negative likelihood ratio | 0.02 (0.00–0.12) | 0.03 (0.01–0.11) | 0.03 (0.01–0.10) | 0.04 (0.02–0.11) |
ACS, acute coronary syndromes; AMI, acute myocardial infarction; T-MACS, Troponin-only Manchester Acute Coronary Syndromes.